Eczema Trial, Recruiting NCT06300697 Sponsor: University of Michigan Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT06300697
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Food allergy only group:

  • People who have been diagnosed by an allergist with a history of severe allergic reactions (anaphylaxis) to peanut, tree nut, egg, milk, or sesame.
  • People who have had skin prick testing and/or blood allergy testing for the relevant food within the past 6 months, with results meeting a specific threshold that strongly indicates allergy (confirm with trial site for exact values).
  • People who have no history of the skin condition atopic dermatitis (also known as eczema).

Food allergy plus atopic dermatitis group:

  • People who meet all the food allergy only criteria above, but who also have a diagnosed history of atopic dermatitis.

Atopic dermatitis without food allergy group:

  • People who currently have a diagnosis of atopic dermatitis confirmed by an allergist and/or dermatologist.
  • People who have no history of food allergy, either now or in the past.

Control group:

  • People who have no history of food allergy or atopic dermatitis, either now or in the past.

Who may not be able to join:

  • People younger than 10 years of age or older than 55 years of age.
  • People with active heart disease, active cancer, lung disease (except well-controlled asthma), or other serious health conditions that would make an oral food challenge (a supervised test where a food is eaten in a clinical setting) unsafe — though mild, well-managed conditions such as controlled high blood pressure may still be acceptable (confirm with trial site).
  • People taking certain medications that cannot be safely stopped temporarily before an oral food challenge, including antihistamines (allergy tablets or liquids) taken within the past week.
  • People with skin conditions other than atopic dermatitis that may affect the study, such as psoriasis, certain inherited skin conditions, or immune-related skin disorders.
  • People who have started or stopped a biologic medication (such as dupilumab or tezepelumab) within the past 6 months.
  • People who have previously undergone or are currently undergoing oral immunotherapy (a treatment programme involving gradually eating increasing amounts of a food allergen) for any food.
  • People who are pregnant — participants of childbearing age will be asked to self-report their pregnancy status.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chase Schuler, MD, University of Michigan

Phone: 734-647-8284

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 February 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Anaphylaxis occurrence rates in each group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov